Pharnext is an advanced clinical-stage biopharmaceutical company developing novel first-in-class therapies for orphan and common diseases with high unmet medical needs, leveraging our artificial intelligence (AI)-based PLEOTHERAPY™ platform.
We strive to address serious unmet medical needs. We believe that diseases require solutions that master their complexity by combining therapeutics in a synergistic and/or additive way. We aim to become the recognized world leader in this approach.
We are dedicated to treating serious chronic diseases by developing novel, first-in-class treatments. We leverage our artificial intelligence (AI)-based PLEOTHERAPY™ platform technology to discover, develop and deliver breakthrough therapies to patients. These therapies consist of repurposed or New Chemical Entity (NCE) drug combinations with potentially high benefit/risk ratio and an accelerated/cost-efficient development pathway.
PLEOTHERAPY™, our proprietary technology platform, is based on network pharmacology. This new and innovative R&D paradigm leverages genomic big data and artificial intelligence tools to systematically develop disease molecular networks: a set of interconnected potential disease targets. These networks are then used to deduce, in silico and experimentally, combinations of generic compounds approved for unrelated indications and/or NCEs to hit multiple highly relevant disease targets. These new therapies, called PLEODRUG™, are formulated at optimal doses offering several potential key advantages including improved efficacy and safety.
PLEODRUG™ candidates are currently in clinical development for the treatment of Charcot-Marie-Tooth disease type 1A and Alzheimer’s disease. We believe that this is just the beginning and that our proprietary technology is poised to provide therapies for any disease.
Meet our team
Explore our history since inception in 2007